Author:
Spirin P V,Lebedev T D,Orlova N N,Gornostaeva A S,Prokofjeva M M,Nikitenko N A,Dmitriev S E,Buzdin A A,Borisov N M,Aliper A M,Garazha A V,Rubtsov P M,Stocking C,Prassolov V S
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference37 articles.
1. Chang KS, Fan YH, Stass SA, Estey EH, Wang G, Trujillo JM et al. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogene 1993; 8: 983–988.
2. Licht JD . AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001; 20: 5660–5679.
3. Guerrasio A, Rosso C, Martinelli G, Lo Coco F, Pampinella M, Santoro A et al. Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission. Br J Haematol 1995; 90: 364–368.
4. Wang J, Saunthararajah Y, Redner RL, Liu JM . Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999; 59: 2766–2769.
5. Hug BA, Lazar MA . ETO interacting proteins. Oncogene 2004; 23: 4270–4274.
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献